Cargando…
The place of VEGF inhibition in the current management of renal cell carcinoma
Vascular endothelial growth factor (VEGF) is overexpressed in around 80% of patients with clear cell carcinoma of the kidney owing to the inactivation of von Hippel Lindau gene activity. VEGF stimulates angiogenesis and acts as an autocrine growth factor. A number of different agents are now availab...
Autores principales: | Nathan, P, Chao, D, Brock, C, Savage, P, Harries, M, Gore, M, Eisen, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361396/ https://www.ncbi.nlm.nih.gov/pubmed/16508632 http://dx.doi.org/10.1038/sj.bjc.6603025 |
Ejemplares similares
-
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
por: Gore, M E, et al.
Publicado: (2011) -
Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011) -
State-of-the-art management of nasopharyngeal carcinoma: current and future directions
por: Agulnik, M, et al.
Publicado: (2005) -
The role of the VEGF-C/VEGFR-3 axis in cancer progression
por: Su, J-L, et al.
Publicado: (2007) -
Mechanisms of adverse effects of anti-VEGF therapy for cancer
por: Kamba, T, et al.
Publicado: (2007)